Jpmorgan Chase & CO Athira Pharma, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 143 shares of ATHA stock, worth $91. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143
Previous 7,537 98.1%
Holding current value
$91
Previous $20,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$1.92 - $2.71 $14,196 - $20,037
-7,394 Reduced 98.1%
143 $0
Q1 2024

May 10, 2024
BUY
$2.24 - $4.15 $16,562 - $30,685
7,394 Added 5170.63%
7,537 $20,000
Q4 2023

Feb 12, 2024
SELL
$1.39 - $2.46 $1,181 - $2,091
-850 Reduced 85.6%
143 $0
Q3 2023

Nov 14, 2023
SELL
$1.9 - $3.16 $76 - $126
-40 Reduced 3.87%
993 $2,000
Q2 2023

Aug 11, 2023
SELL
$2.36 - $3.59 $61,371 - $93,357
-26,005 Reduced 96.18%
1,033 $3,000
Q1 2023

May 18, 2023
BUY
$2.26 - $4.22 $58,861 - $109,909
26,045 Added 2622.86%
27,038 $67,000
Q1 2023

May 11, 2023
SELL
$2.26 - $4.22 $44,076 - $82,302
-19,503 Reduced 95.16%
993 $2,000
Q4 2022

Feb 13, 2023
SELL
$2.76 - $3.71 $1,512 - $2,033
-548 Reduced 2.6%
20,496 $65,000
Q3 2022

Nov 14, 2022
BUY
$2.93 - $3.96 $3,823 - $5,167
1,305 Added 6.61%
21,044 $62,000
Q2 2022

Aug 11, 2022
BUY
$2.74 - $13.43 $654 - $3,209
239 Added 1.23%
19,739 $60,000
Q1 2022

May 11, 2022
BUY
$8.96 - $13.51 $34,666 - $52,270
3,869 Added 24.75%
19,500 $263,000
Q4 2021

Feb 10, 2022
SELL
$9.17 - $16.39 $714,012 - $1.28 Million
-77,864 Reduced 83.28%
15,631 $204,000
Q3 2021

Nov 12, 2021
BUY
$9.15 - $11.09 $855,479 - $1.04 Million
93,495 New
93,495 $877,000

Others Institutions Holding ATHA

# of Institutions
75
Shares Held
23.1M
Call Options Held
73.4K
Put Options Held
97.8K
View Full List

About Athira Pharma, Inc.

ATHA Quotes by TradingView
  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.2M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email